ArticleFrontiers in cellular and infection microbiology2026
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polymicrobial bone infections (PBIs) are associated with greater clinical severity and present more significant therapeutic challenges than monomicrobial infections. Methicillin-resistant Methods: Under Results: At an MRSA: PA ratio of 1:1, MRSA CFU remained close to the initial inoculum throughout the experiment, with maximum CFU reaching only 1% of that in monoculture. MRSA biofilm biomass in the presence of PA cell-free supernatant was reduced by 33% at 36 hours. Notably, antibiotic susceptibility testing showed that MRSA exhibited increased MIC values for levofloxacin and daptomycin, with MICs 1.53 ± 0.00-fold and 2.00 ± 0.00-fold higher, respectively, than those in the monoculture group. Meanwhile, PA showed increased MIC values to colistin, with a 2.00 ± 0.00-fold higher MIC, but reduced MIC values for levofloxacin and ceftazidime, both showing a 0.50 ± 0.00-fold lower MIC compared with the monoculture group. Transcriptomic analysis of MRSA revealed significant increases in gene expression related to ribosome biogenesis, oxidative phosphorylation, and stress response pathways. PA co-cultured with MRSA downregulated multidrug-resistant efflux pump genes and upregulated pore-forming protein genes. Conclusion: PA inhibited MRSA growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.